fact - luye and abs $60m prime valuation, page-25

Although you guys keep eyes on the upcoming Full year financial announcement, I think the funding strategy for NSP's subsidaries is already quite clear.

1, PrIME: NSP will transfer (sell) 50% of its 100% owned PrIME pty ltd in Singapore for AUD$23 million, first $4.6m settled.

NSP will be free carried 50% as operator.

Asian market target: $1.8 billion per year.

2, SpermGen: NSP will transfer (sell) 50% of its 100% owned SpermGen pty ltd. "To this end the Company is evaluating similar investment possibilities for the
SpermSep application of the PrIME technology" offers received.

NSP will be free carried 50% as operator.

Global market target : $60m-100m

3,The Australian subsidiary, NuSep P/L will manufacture all the membranes for the various applications including plasma and sperm. This will provide a significant revenue stream for NuSep P/L and based on PrIME’s budget could be NuSep P/L’s main revenue stream within 3 years.

NSP will 100% own NuSep pty ltd as global headquarter, funded by existing Gel sales revenue, and off take order from the above 2 subsidiaries.

I believe NSP has well solved the funding for each subsidiary and start expanding into India through ABS partnership.